Larry Lasky, PhD joined healthcare venture capital firm The Column Group in 2014. He has worked in the biotechnology industry for over 30 years. In 1981, he was a founding scientist of the Genetics Institute, acquired by Wyeth, one of the earliest biotechnology companies. Dr. Lasky was subsequently a leading scientist at Genentech and eventually a Genentech Fellow. He worked in various disciplines including vaccinology, immunology, stem cell biology, cellular signaling mechanisms and monoclonal antibody therapy of tumors. He is a co-author on over 135 publications and a co-inventor on 37 issued and pending patents. In addition to serving on Accent’s board of directors, he served on the board of eFFECTOR Therapeutics and Revolution Medicines and serves on the scientific advisory board for Ribon Therapeutics and Eikon Therapeutics.